SCHEMBL22925973

SCHEMBL22925973

N/C(=N\O)c1ccc(Nc2ncc(-c3ccc(OC(F)(F)F)cn3)o2)cn1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36
MAPT P10636 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
RAF1 P04049 1/20 0.33
BRAF P15056 1/20 0.33
GRM4 Q14833 1/20 0.33
VCP P55072 4/20 0.33
BACE1 P56817 1/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
KDR P35968 2/20 0.32
FLT1 P17948 1/20 0.32
FLT4 P35916 1/20 0.32
ABL1 P00519 2/20 0.32
BCR P11274 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28733764 1.00 MEN1 (0.36) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL24636896 0.89 VCP (0.41) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL29696270 0.89 VCP (0.41) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL28733637 0.86 KMT2A (0.40) KMT2AVCPKDRFLT1FLT4
SCHEMBL22925928 0.86 KMT2A (0.40) KMT2AVCPKDRFLT1FLT4
SCHEMBL22925740 0.85 ALOX5 (0.39) VCPKDRFLT1FLT4ALOX5
SCHEMBL22925766 0.85 ALOX5 (0.39) VCPKDRFLT1FLT4ALOX5
SCHEMBL29696308 0.85 ALOX5 (0.39) VCPKDRFLT1FLT4ALOX5
SCHEMBL22925938 0.83 TUBB4A (0.35) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL28939251 0.83 TUBB4A (0.35) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220274970-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2022-09-01 US disclosed
WO-2021012018-A1 INHIBITOR COMPOUNDS Cincera Therapeutics Pty Ltd (AU) 2021-01-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220274970-A1 INHIBITOR COMPOUNDS SERPINB1, MMP1, SSB MEN1 1826/4885KMT2A 3735/4885NPC1 663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.